Intuitive Surgical's Q4 2024 Conference Call Highlights Robust Procedure Growth, Strong Financial Performance
Intuitive Surgical, a leading medical technology company, has reported strong financial performance and robust procedure growth for the fourth quarter of 2024. The company's quarterly earnings conference call provided insights into its full-year and quarterly results, as well as its outlook for 2025.
According to Gary Guthart, CEO of Intuitive Surgical, 2024 was a "strong year" for the company, marked by robust early adoption of its fifth-generation multiport platform, da Vinci 5. The company reported 17% growth in procedures for the full year, driven by strong performance in general surgery in the United States and regional markets such as the UK and Ireland, Japan, and Germany.
"We expanded indications and launches of our new platforms by region, with a particular focus on our first phase of da Vinci 5 launch," Guthart explained. "We also pursued increased adoption for focused procedures by country through training, commercial activities, and market access efforts."
Procedure growth outside the United States continued to diversify beyond urology, with strong growth in categories including general surgery and thoracic surgery. Globally, benign indications grew approximately 200 basis points faster than cancer indications.
The company's financial performance was also robust, with adoption of its Ion and da Vinci SP platforms continuing to grow. The acquisition from AB Medica of the da Vinci business in Italy, Spain, Portugal, and related territories is expected to further drive growth.
"We're pleased with their performance, and we look forward to welcoming these new staff to our team," Guthart said.
Looking ahead to 2025, Intuitive Surgical's CEO emphasized the company's focus on increasing productivity, particularly in functions that benefit from industrial scale. The company also plans to continue improving its products across all three of its platforms and helping customers achieve their programmatic objectives.
The conference call provided a detailed review of the company's financial results, procedure highlights, and outlook for 2025. Intuitive Surgical's strong performance in Q4 2024 is expected to drive growth in the year ahead.
